ATE401877T1 - Verwendung von methylenamid-derivaten bei kardiovaskulären erkrankungen - Google Patents

Verwendung von methylenamid-derivaten bei kardiovaskulären erkrankungen

Info

Publication number
ATE401877T1
ATE401877T1 AT05716814T AT05716814T ATE401877T1 AT E401877 T1 ATE401877 T1 AT E401877T1 AT 05716814 T AT05716814 T AT 05716814T AT 05716814 T AT05716814 T AT 05716814T AT E401877 T1 ATE401877 T1 AT E401877T1
Authority
AT
Austria
Prior art keywords
derivatives
methylenamide
cardiovascular diseases
prevention
formula
Prior art date
Application number
AT05716814T
Other languages
English (en)
Inventor
Van Huijsduijnen Rob Hooft
Vincent Richard
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Application granted granted Critical
Publication of ATE401877T1 publication Critical patent/ATE401877T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT05716814T 2004-02-27 2005-02-25 Verwendung von methylenamid-derivaten bei kardiovaskulären erkrankungen ATE401877T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04100778 2004-02-27

Publications (1)

Publication Number Publication Date
ATE401877T1 true ATE401877T1 (de) 2008-08-15

Family

ID=34896106

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05716814T ATE401877T1 (de) 2004-02-27 2005-02-25 Verwendung von methylenamid-derivaten bei kardiovaskulären erkrankungen

Country Status (23)

Country Link
US (1) US20070185118A1 (de)
EP (1) EP1732534B1 (de)
JP (1) JP5001138B2 (de)
KR (1) KR101188940B1 (de)
CN (1) CN1933827B (de)
AT (1) ATE401877T1 (de)
AU (1) AU2005216649B2 (de)
BR (1) BRPI0508080A (de)
CA (1) CA2554919C (de)
CY (1) CY1108252T1 (de)
DE (1) DE602005008412D1 (de)
DK (1) DK1732534T3 (de)
EA (1) EA011811B1 (de)
ES (1) ES2308458T3 (de)
HR (1) HRP20080367T3 (de)
IL (1) IL177494A (de)
NO (1) NO20064295L (de)
PL (1) PL1732534T3 (de)
PT (1) PT1732534E (de)
RS (1) RS50596B (de)
SI (1) SI1732534T1 (de)
UA (1) UA84453C2 (de)
WO (1) WO2005082347A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE510817T1 (de) * 2002-01-29 2011-06-15 Merck Serono Sa Substituierte methylenamidderivate als modulatoren von proteintyrosinphosphatasen (ptps)
AU2004261400A1 (en) 2003-07-21 2005-02-10 Laboratoires Serono Sa Alkynyl aryl carboxamides
AU2007307599A1 (en) 2006-10-12 2008-04-17 Institute Of Medicinal Molecular Design. Inc. N-phenyloxamic acid derivatives
US8633245B2 (en) * 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
JP2014525501A (ja) 2011-08-29 2014-09-29 ティコナ・エルエルシー 高流動性液晶ポリマー組成物
WO2013032967A1 (en) 2011-08-29 2013-03-07 Ticona Llc Cast molded parts formed form a liquid crystalline polymer
CN103764741B (zh) 2011-08-29 2015-09-23 提克纳有限责任公司 低熔体粘度液晶聚合物的熔融聚合
WO2013032977A1 (en) 2011-08-29 2013-03-07 Ticona Llc Heat-resistant liquid crystalline polymer composition having a low melting temperature
US8669341B2 (en) 2011-08-29 2014-03-11 Ticona Llc Solid-state polymerization of a liquid crystalline polymer
TW201319023A (zh) 2011-08-29 2013-05-16 Ticona Llc 具改良低剪切黏度之熱向性液晶聚合物
KR20140059825A (ko) 2011-08-29 2014-05-16 티코나 엘엘씨 고유동성 액정 중합체 조성물
CN103764623B (zh) 2011-08-29 2016-04-27 提克纳有限责任公司 芳族酰胺化合物
US8852730B2 (en) 2011-08-29 2014-10-07 Ticona Llc Melt-extruded substrate for use in thermoformed articles
WO2014095815A1 (en) 2012-12-17 2014-06-26 Shell Internationale Research Maatschappij B.V. Integrated gas-to-liquid condensate process
WO2014130275A2 (en) 2013-02-22 2014-08-28 Ticona Llc High performance polymer composition with improved flow properties
US9206300B2 (en) 2013-06-07 2015-12-08 Ticona Llc High strength thermotropic liquid crystalline polymer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019830A1 (en) * 1999-09-10 2001-03-22 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
US6627767B2 (en) * 2000-08-29 2003-09-30 Abbott Laboratories Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors
DE10117823A1 (de) * 2001-04-10 2002-10-17 Merck Patent Gmbh Oxalsäurederivate
AR034374A1 (es) * 2001-06-07 2004-02-18 Wyeth Corp Combinacion de un inhibidor de ptpasa y un inhibidor de ace
WO2002098408A1 (en) * 2001-06-07 2002-12-12 Wyeth Ptpase inhibitors for improving cardiovascular risk profile
ATE510817T1 (de) * 2002-01-29 2011-06-15 Merck Serono Sa Substituierte methylenamidderivate als modulatoren von proteintyrosinphosphatasen (ptps)

Also Published As

Publication number Publication date
JP5001138B2 (ja) 2012-08-15
WO2005082347A1 (en) 2005-09-09
JP2007524701A (ja) 2007-08-30
AU2005216649B2 (en) 2010-09-09
HK1098073A1 (en) 2007-07-13
NO20064295L (no) 2006-09-22
KR20060129066A (ko) 2006-12-14
RS50596B (sr) 2010-05-07
KR101188940B1 (ko) 2012-10-08
ES2308458T3 (es) 2008-12-01
EP1732534A1 (de) 2006-12-20
CN1933827B (zh) 2011-07-27
EA200601511A1 (ru) 2007-02-27
SI1732534T1 (sl) 2008-10-31
CA2554919C (en) 2013-04-16
IL177494A0 (en) 2006-12-31
EP1732534B1 (de) 2008-07-23
BRPI0508080A (pt) 2007-07-17
DK1732534T3 (da) 2008-11-17
IL177494A (en) 2011-06-30
PL1732534T3 (pl) 2008-12-31
CN1933827A (zh) 2007-03-21
HRP20080367T3 (en) 2008-09-30
PT1732534E (pt) 2008-08-08
CY1108252T1 (el) 2014-02-12
CA2554919A1 (en) 2005-09-09
DE602005008412D1 (de) 2008-09-04
US20070185118A1 (en) 2007-08-09
AU2005216649A1 (en) 2005-09-09
EA011811B1 (ru) 2009-06-30
UA84453C2 (ru) 2008-10-27

Similar Documents

Publication Publication Date Title
CY1108252T1 (el) Χρηση παραγωγων μεθυλενο αμιδης στις καρδιαγγειακες διαταραχες
ATE551059T1 (de) Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
ATE453393T1 (de) Verwendung von pyridylamiden als angiogenesehemmer
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
NO20062561L (no) Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
DE602007009095D1 (de) Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase
ATE478044T1 (de) Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c
NO20070933L (no) Indazoler anvendbare i behandling av kardiovaskulaere sykdommer
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
NO20071343L (no) Substituerte fenylaminotiazoler og anvendelse derav
NZ548954A (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EA200870019A1 (ru) Лактамовые соединения и способы их применения
DE602004022668D1 (de) 5-gliedrige heterocyclische p-38 inhibitoren
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
NO20071574L (no) Arylsulfonylstilbenderivater for behandling av insomni og beslektede tilstander.
ATE331709T1 (de) Substituierte 3-carbonyl-1-yl essigsäure derivate als plasminogen aktivator inhibitor(pai-1) inhibitoren
ATE413392T1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
DE602006006985D1 (de) Pyridinderivate als pkc-theta-hemmer
ATE411984T1 (de) Neue kondensierte n-pyrazinyl-sulfonamide und deren verwendung bei der behandlung von chemokinvermittelten krankheiten
ATE407119T1 (de) Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors
NO20052655L (no) Sammensmeltede heterocykliske forbindelser
MX2008009161A (es) Tratamiento de enfermedad cardiovascular en mexicano-americanos, usando nebivolol.
EP1812007A4 (de) Pyridazinverbindungen und verfahren
DE602005008099D1 (de) Pyrrolopyridin-2-karbonsäureamid-derivat zur verwendung als inhibitor gegen glykogenphosphorylase
BR0315092A (pt) Derivados de piperidina como inibidores de ccr5

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1732534

Country of ref document: EP

EEFA Change of the company name